Raras
Buscar doenças, sintomas, genes...
Osteopetrose
ORPHA:2781CID-10 · Q78.2CID-11 · LD24.10DOENÇA RARA

A Osteopetrose, também conhecida como doença dos ossos de mármore, é um termo que descreve um grupo de doenças raras e hereditárias que afetam os ossos do corpo. Elas são caracterizadas por uma densidade óssea maior do que o normal, visível em exames de raio-X.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Osteopetrose, também conhecida como doença dos ossos de mármore, é um termo que descreve um grupo de doenças raras e hereditárias que afetam os ossos do corpo. Elas são caracterizadas por uma densidade óssea maior do que o normal, visível em exames de raio-X.

Pesquisas ativas
2 ensaios
27 total registrados no ClinicalTrials.gov
Publicações científicas
1 artigos
Último publicado: 2002

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q78.2
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
83 sintomas
😀
Face
35 sintomas
🧠
Neurológico
27 sintomas
👁️
Olhos
19 sintomas
🦷
Dentes
13 sintomas
🩸
Sangue
13 sintomas

+ 143 sintomas em outras categorias

Características mais comuns

Bossas frontais
Rizomelia
Laringomalácia
Anormalidade da clavícula
Dedo curto
Pé curto
401sintomas
Sem dados (401)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 401 características clínicas mais associadas, ordenadas por frequência.

Bossas frontaisFrontal bossing
RizomeliaRhizomelia
LaringomaláciaLaryngomalacia
Anormalidade da clavículaAbnormality of the clavicle
Dedo curtoShort finger

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1PubMed
Últimos 10 anos171publicações
Pico202125 papers
Linha do tempo
2026Hoje · 2026🧪 1999Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

19 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, X-linked recessive.

FERMT3Fermitin family homolog 3Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Plays a central role in cell adhesion in hematopoietic cells (PubMed:19234463, PubMed:26359933). Acts by activating the integrin beta-1-3 (ITGB1, ITGB2 and ITGB3) (By similarity). Required for integrin-mediated platelet adhesion and leukocyte adhesion to endothelial cells (PubMed:19234460). Required for activation of integrin beta-2 (ITGB2) in polymorphonuclear granulocytes (PMNs) (By similarity) Isoform 2 may act as a repressor of NF-kappa-B and apoptosis

LOCALIZAÇÃO

Cell projection, podosome

VIAS BIOLÓGICAS (1)
Platelet degranulation
MECANISMO DE DOENÇA

Leukocyte adhesion deficiency 3

A disorder characterized by recurrent bacterial infections without pus formation, leukocytosis and major bleeding disorders.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
258.2 TPM
Linfócitos
220.1 TPM
Baço
175.3 TPM
Pulmão
75.3 TPM
Intestino delgado
36.9 TPM
OUTRAS DOENÇAS (1)
leukocyte adhesion deficiency 3
HGNC:23151UniProt:Q86UX7
CTNNB1Catenin beta-1Candidate gene tested inAltamente restrito
FUNÇÃO

Key downstream component of the canonical Wnt signaling pathway (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, PubMed:22155184, PubMed:22647378, PubMed:22699938). In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:189574

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeletonCell junction, adherens junctionCell junctionCell membraneCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindle poleSynapseCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (10)
Formation of the nephric ductSpecification of the neural plate borderSynthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)TCF dependent signaling in response to WNTTranscriptional Regulation by VENTX
MECANISMO DE DOENÇA

Colorectal cancer

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
297.5 TPM
Cervix Ectocervix
257.8 TPM
Artéria tibial
233.5 TPM
Ovário
201.9 TPM
Cérebro - Hemisfério cerebelar
201.3 TPM
OUTRAS DOENÇAS (17)
hepatocellular carcinomasevere intellectual disability-progressive spastic diplegia syndromeovarian cancerpilomatrixoma
HGNC:2514UniProt:P35222
IKBKGNF-kappa-B essential modulatorCandidate gene tested inAltamente restrito
FUNÇÃO

Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor (PubMed:14695475, PubMed:20724660, PubMed:21518757, PubMed:9751060). Its binding to scaffolding polyubiquitin plays a key role in IKK activation by multiple signaling receptor pathways (PubMed:16547522, PubMed:18287044, PubMed:19033441, PubMed:19185524, PubMed:21606507, PubMed:27777308, PubMed

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
SARS-CoV-2 activates/modulates innate and adaptive immune responsesNOD1/2 Signaling PathwayTAK1-dependent IKK and NF-kappa-B activation Interleukin-1 signalingJNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
MECANISMO DE DOENÇA

Ectodermal dysplasia and immunodeficiency 1

A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. EDAID1 is an X-linked recessive disorder characterized by absence of sweat glands, sparse scalp hair, rare conical teeth and immunological abnormalities resulting in severe infectious diseases. Severely affected individuals may also show lymphedema, osteopetrosis, and, rarely, hematologic abnormalities. The phenotype is highly variable, and may be fatal in childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
7.4 TPM
Sangue
7.3 TPM
Baço
7.2 TPM
Pulmão
7.0 TPM
Útero
6.7 TPM
OUTRAS DOENÇAS (6)
incontinentia pigmentiectodermal dysplasia and immunodeficiency 1autoinflammatory disease, X-linkedimmunodeficiency 33
HGNC:5961UniProt:Q9Y6K9
CSF1RMacrophage colony-stimulating factor 1 receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Other interleukin signalingTranscriptional Regulation by VENTXSignaling by CSF1 (M-CSF) in myeloid cells
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
206.9 TPM
Nervo tibial
49.7 TPM
Tecido adiposo
38.0 TPM
Pulmão
37.9 TPM
Adipose Visceral Omentum
34.3 TPM
OUTRAS DOENÇAS (3)
leukoencephalopathy, diffuse hereditary, with spheroids 1brain abnormalities, neurodegeneration, and dysosteosclerosisearly-onset calcifying leukoencephalopathy-skeletal dysplasia
HGNC:2433UniProt:P07333
SLC29A3Equilibrative nucleoside transporter 3Candidate gene tested inTolerante
FUNÇÃO

Uniporter that mediates the facilitative transport of nucleoside across lysosomal and mitochondrial membranes (PubMed:15701636, PubMed:19164483, PubMed:20595384, PubMed:28729424). Functions as a non-electrogenic Na(+)-independent transporter (PubMed:15701636, PubMed:19164483, PubMed:28729424). Substrate transport is pH-dependent and enhanced under acidic condition, probably reflecting the location of the transporter in acidic intracellular compartments (PubMed:15701636, PubMed:19164483, PubMed:2

LOCALIZAÇÃO

Lysosome membraneLate endosome membraneMitochondrion membraneCell membrane

VIAS BIOLÓGICAS (1)
Ribavirin ADME
MECANISMO DE DOENÇA

Histiocytosis-lymphadenopathy plus syndrome

A syndrome characterized by the combination of features from 2 or more of four histiocytic disorders, originally thought to be distinct: Faisalabad histiocytosis (FHC), sinus histiocytosis with massive lymphadenopathy (SHML), H syndrome, and pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome (PHID). FHC features include joint deformities, sensorineural hearing loss, and subsequent development of generalized lymphadenopathy and swellings in the eyelids that contain histiocytes. SHML causes lymph node enlargement in children frequently accompanied by fever, leukocytosis, elevated erythrocyte sedimentation rate, and polyclonal hypergammaglobulinemia. H syndrome is characterized by cutaneous hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart anomalies, and hypogonadism; hearing loss is found in about half of patients. PHID is characterized by predominantly antibody-negative insulin-dependent diabetes mellitus associated with pigmented hypertrichosis and variable occurrence of other features of H syndrome.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
18.6 TPM
Cervix Endocervix
15.7 TPM
Útero
15.5 TPM
Cervix Ectocervix
12.2 TPM
Fallopian Tube
11.8 TPM
OUTRAS DOENÇAS (2)
H syndromedysosteosclerosis
HGNC:23096UniProt:Q9BZD2
SLC4A2Anion exchange protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sodium-independent anion exchanger which mediates the electroneutral exchange of chloride for bicarbonate ions across the cell membrane (PubMed:15184086, PubMed:34668226). Plays an important role in osteoclast differentiation and function (PubMed:34668226). Regulates bone resorption and calpain-dependent actin cytoskeleton organization in osteoclasts via anion exchange-dependent control of pH (By similarity). Essential for intracellular pH regulation in CD8(+) T-cells upon CD3 stimulation, modul

LOCALIZAÇÃO

Apical cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Bicarbonate transporters
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 9

A form of osteopetrosis, a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB9 is characterized by increased bone density and bone fragility, as well as renal failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
57.0 TPM
Estômago
56.9 TPM
Útero
55.4 TPM
Cervix Ectocervix
50.9 TPM
Cólon sigmoide
49.9 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
osteopetrosis, autosomal recessive 9
HGNC:HGNC:11028UniProt:P04920
LRP5Low-density lipoprotein receptor-related protein 5Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins (PubMed:11336703, PubMed:11448771, PubMed:11719191, PubMed:15778503, PubMed:15908424, PubMed:16252235). Activates the canonical Wnt signaling pathway that controls cell fate determination and self-renewal during embryonic development and adult tissue regeneration (PubMed:11336703, PubMed:11719191). In particular, may play an important role in the development of t

LOCALIZAÇÃO

MembraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
MECANISMO DE DOENÇA

Vitreoretinopathy, exudative 1

An autosomal dominant disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. In many ways the disease resembles retinopathy of prematurity but there is no evidence of prematurity or small birth weight in the patient history.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
83.2 TPM
Artéria tibial
67.8 TPM
Glândula salivar
64.2 TPM
Útero
56.7 TPM
Tireoide
51.4 TPM
OUTRAS DOENÇAS (12)
polycystic liver disease 4 with or without kidney cystsobsolete bone mineral density quantitative trait locus 1autosomal dominant osteosclerosis, Worth typeosteoporosis-pseudoglioma syndrome
HGNC:6697UniProt:O75197
CTSKCathepsin KDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Thiol protease involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Involved in the release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (PubMed:11082042)

LOCALIZAÇÃO

LysosomeSecretedApical cell membrane

VIAS BIOLÓGICAS (2)
RUNX1 regulates transcription of genes involved in differentiation of keratinocytesMHC class II antigen presentation
MECANISMO DE DOENÇA

Pycnodysostosis

A rare autosomal recessive bone disorder characterized by deformity of the skull, maxilla and phalanges, osteosclerosis, and fragility of bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
669.9 TPM
Cervix Endocervix
642.5 TPM
Fibroblastos
347.3 TPM
Tecido adiposo
285.8 TPM
Útero
282.5 TPM
OUTRAS DOENÇAS (1)
pycnodysostosis
HGNC:2536UniProt:P43235
TNFRSF11ATumor necrosis factor receptor superfamily member 11ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis (PubMed:9878548). Its interaction with EEIG1 promotes osteoclastogenesis via facilitating the transcription of NFATC1 and activation of PLCG2 (By similarity). Involved in the regulation of interactions between T-cells and dendritic cells (By similarity)

LOCALIZAÇÃO

Cell membraneMembrane raft

VIAS BIOLÓGICAS (2)
TNFR2 non-canonical NF-kB pathwayTNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
MECANISMO DE DOENÇA

Familial expansile osteolysis

Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
10.6 TPM
Pituitária
9.9 TPM
Cólon transverso
8.4 TPM
Intestino delgado
7.9 TPM
Skin Sun Exposed Lower leg
2.8 TPM
OUTRAS DOENÇAS (6)
familial expansile osteolysisautosomal recessive osteopetrosis 7adult-onset myasthenia gravisdysosteosclerosis
HGNC:11908UniProt:Q9Y6Q6
AMER1APC membrane recruitment protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Regulator of the canonical Wnt signaling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signaling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signaling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regu

LOCALIZAÇÃO

CytoplasmCell membraneNucleus

VIAS BIOLÓGICAS (10)
Disassembly of the destruction complex and recruitment of AXIN to the membraneDegradation of beta-catenin by the destruction complexCTNNB1 T41 mutants aren't phosphorylatedCTNNB1 S33 mutants aren't phosphorylatedCTNNB1 S37 mutants aren't phosphorylated
MECANISMO DE DOENÇA

Osteopathia striata with cranial sclerosis

An X-linked dominant sclerosing bone dysplasia that presents in females with macrocephaly, cleft palate, facial palsy, conductive hearing loss, mild learning disabilities, sclerosis of the long bones and skull. Longitudinal striations are visible on radiographs of the long bones, pelvis, and scapulae (osteopathia striata). In males this entity is usually associated with fetal or neonatal lethality. Occasional surviving males have, in addition to hyperostosis, cardiac, intestinal, and genitourinary malformations.

OUTRAS DOENÇAS (1)
osteopathia striata with cranial sclerosis
HGNC:26837UniProt:Q5JTC6
OSTM1Osteopetrosis-associated transmembrane protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for osteoclast and melanocyte maturation and function

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 5

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB5 patients manifest primary central nervous system involvement in addition to the classical stigmata of severe bone sclerosis, growth failure, anemia, thrombocytopenia and visual impairment with optic atrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
42.5 TPM
Aorta
32.9 TPM
Artéria coronária
32.7 TPM
Esôfago - Muscular
26.2 TPM
Cólon sigmoide
25.0 TPM
OUTRAS DOENÇAS (2)
autosomal recessive osteopetrosis 5infantile osteopetrosis with neuroaxonal dysplasia
HGNC:21652UniProt:Q86WC4
CA2Carbonic anhydrase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible hydration of carbon dioxide (PubMed:11327835, PubMed:11802772, PubMed:11831900, PubMed:12056894, PubMed:12171926, PubMed:1336460, PubMed:14736236, PubMed:15300855, PubMed:15453828, PubMed:15667203, PubMed:15865431, PubMed:16106378, PubMed:16214338, PubMed:16290146, PubMed:16686544, PubMed:16759856, PubMed:16807956, PubMed:17127057, PubMed:17251017, PubMed:17314045, PubMed:17330962, PubMed:17346964, PubMed:17540563, PubMed:17588751, PubMed:17705204, PubMed:18024029, PubMe

LOCALIZAÇÃO

CytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Erythrocytes take up carbon dioxide and release oxygenErythrocytes take up oxygen and release carbon dioxideReversible hydration of carbon dioxideDevelopmental Lineage of Pancreatic Ductal Cells
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 3

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB3 is associated with renal tubular acidosis, cerebral calcification (marble brain disease) and in some cases with intellectual disability.

OUTRAS DOENÇAS (1)
autosomal recessive osteopetrosis 3
HGNC:1373UniProt:P00918
TNFSF11Tumor necrosis factor ligand superfamily member 11Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by

LOCALIZAÇÃO

Cell membraneCytoplasmSecreted

VIAS BIOLÓGICAS (4)
TNFR2 non-canonical NF-kB pathwayTNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathwayTNFs bind their physiological receptorsTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 2

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
14.7 TPM
Testículo
1.7 TPM
Intestino delgado
0.6 TPM
Fígado
0.3 TPM
Baço
0.2 TPM
OUTRAS DOENÇAS (2)
autosomal recessive osteopetrosis 2autosomal recessive osteopetrosis
HGNC:11926UniProt:O14788
PLEKHM1Pleckstrin homology domain-containing family M member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts as a multivalent adapter protein that regulates Rab7-dependent and HOPS complex-dependent fusion events in the endolysosomal system and couples autophagic and the endocytic trafficking pathways. Acts as a dual effector of RAB7A and ARL8B that simultaneously binds these GTPases, bringing about clustering and fusion of late endosomes and lysosomes (PubMed:25498145, PubMed:28325809). Required for late stages of endolysosomal maturation, facilitating both endocytosis-mediated degradation of gro

LOCALIZAÇÃO

Autolysosome membraneEndosome membraneLate endosome membraneLysosome membrane

MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 6

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
41.0 TPM
Cerebelo
25.4 TPM
Cérebro - Hemisfério cerebelar
22.4 TPM
Skin Sun Exposed Lower leg
21.8 TPM
Vagina
21.3 TPM
OUTRAS DOENÇAS (2)
osteopetrosis, autosomal dominant 3autosomal recessive osteopetrosis 6
HGNC:29017UniProt:Q9Y4G2
TCIRG1V-type proton ATPase 116 kDa subunit a 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (By similarity). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Seems to be directly involved in T-cell a

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (3)
Insulin receptor recyclingTransferrin endocytosis and recyclingIon channel transport
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 1

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
473.7 TPM
Baço
357.4 TPM
Cervix Endocervix
257.4 TPM
Pulmão
249.1 TPM
Cervix Ectocervix
190.2 TPM
OUTRAS DOENÇAS (5)
autosomal recessive osteopetrosis 1autosomal dominant severe congenital neutropeniadysosteosclerosisautosomal recessive osteopetrosis
HGNC:11647UniProt:Q13488
CLCN7H(+)/Cl(-) exchange transporter 7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Slowly voltage-gated channel mediating the exchange of chloride ions against protons (PubMed:18449189, PubMed:21527911). Functions as antiporter and contributes to the acidification of the lysosome lumen and may be involved in maintaining lysosomal pH (PubMed:18449189, PubMed:21527911, PubMed:31155284). The CLC channel family contains both chloride channels and proton-coupled anion transporters that exchange chloride or another anion for protons (By similarity). The presence of conserved gating

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Stimuli-sensing channels
MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 4

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves.

VIAS REACTOME (1)
OUTRAS DOENÇAS (5)
autosomal dominant osteopetrosis 2autosomal recessive osteopetrosis 4hypopigmentation, organomegaly, and delayed myelination and developmentautosomal recessive osteopetrosis
HGNC:2025UniProt:P51798
LRRK1Leucine-rich repeat serine/threonine-protein kinase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine-protein kinase which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231). Phosphorylates RAB7A; this activity is dependent on protein kinase C (PKC) activation (PubMed:36040231, PubMed:37558661, PubMed:37857821). Plays a role in the negative regulation of bone mass, acting through the maturation of osteoclasts (By similarity)

LOCALIZAÇÃO

CytoplasmCell membrane

MECANISMO DE DOENÇA

Osteosclerotic metaphyseal dysplasia

An autosomal recessive skeletal dysplasia characterized by osteosclerosis at multiple skeletal sites, predominantly at the metaphyses of the long bones and vertebral bodies.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
19.0 TPM
Baço
10.5 TPM
Cervix Endocervix
9.7 TPM
Útero
9.0 TPM
Intestino delgado
8.4 TPM
OUTRAS DOENÇAS (1)
osteosclerotic metaphyseal dysplasia
HGNC:18608UniProt:Q38SD2
SNX10Sorting nexin-10Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable phosphoinositide-binding protein involved in protein sorting and membrane trafficking in endosomes. Plays a role in cilium biogenesis through regulation of the transport and the localization of proteins to the cilium. Required for the localization to the cilium of V-ATPase subunit ATP6V1D and ATP6V0D1, and RAB8A. Involved in osteoclast differentiation and therefore bone resorption

LOCALIZAÇÃO

CytoplasmEndosome membraneCytoplasm, cytoskeleton, microtubule organizing center, centrosome

MECANISMO DE DOENÇA

Osteopetrosis, autosomal recessive 8

A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB8 is clinically characterized by dense bones with no distinction between outer and inner plates, due to extensive encroachment of cortical bone into the medullary space, increased head circumference, broad open fontanelle, frontal bossing, and hepatosplenomegaly. Osteoclasts number is low and their bone resorptive capacity is impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
60.8 TPM
Hipotálamo
40.1 TPM
Brain Anterior cingulate cortex BA24
38.5 TPM
Linfócitos
33.5 TPM
Cérebro - Hemisfério cerebelar
27.4 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
autosomal recessive osteopetrosis 8autosomal recessive osteopetrosis
HGNC:14974UniProt:Q9Y5X0
MAP2K1Dual specificity mitogen-activated protein kinase kinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, spindle pole bodyCytoplasmNucleusMembrane

VIAS BIOLÓGICAS (10)
MAP2K and MAPK activationFrs2-mediated activationSignaling downstream of RAS mutantsSignaling by high-kinase activity BRAF mutantsSignaling by moderate kinase activity BRAF mutants
MECANISMO DE DOENÇA

Cardiofaciocutaneous syndrome 3

A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
99.1 TPM
Cérebro - Hemisfério cerebelar
89.3 TPM
Brain Frontal Cortex BA9
87.1 TPM
Brain Nucleus accumbens basal ganglia
71.7 TPM
Brain Anterior cingulate cortex BA24
55.9 TPM
OUTRAS DOENÇAS (5)
melorheostosiscardiofaciocutaneous syndrome 3cardiofaciocutaneous syndromeRASopathy
HGNC:6840UniProt:Q02750

Variantes genéticas (ClinVar)

729 variantes patogênicas registradas no ClinVar.

🧬 FERMT3: NM_031471.6(FERMT3):c.1295_1296insACTGCGGTGCCAGGATGTGAGTGAGATCTA (p.Tyr432Ter) ()
🧬 FERMT3: NM_031471.6(FERMT3):c.224del (p.Gln75fs) ()
🧬 FERMT3: NM_031471.6(FERMT3):c.1462del (p.His488fs) ()
🧬 FERMT3: NM_031471.6(FERMT3):c.786+258G>T ()
🧬 FERMT3: NM_031471.6(FERMT3):c.-14-9T>A ()
Ver todas no ClinVar

Vias biológicas (Reactome)

111 vias biológicas associadas aos genes desta condição.

Platelet degranulation Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 SUMOylation of immune response proteins Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Other interleukin signaling Signaling by CSF1 (M-CSF) in myeloid cells Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS) Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane Ribavirin ADME Bicarbonate transporters Negative regulation of TCF-dependent signaling by WNT ligand antagonists Regulation of FZD by ubiquitination Signaling by LRP5 mutants Signaling by RNF43 mutants Collagen degradation Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Trafficking and processing of endosomal TLR MHC class II antigen presentation RUNX1 regulates transcription of genes involved in differentiation of keratinocytes TNFR2 non-canonical NF-kB pathway TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Neddylation KEAP1-NFE2L2 pathway Stimuli-sensing channels Erythrocytes take up carbon dioxide and release oxygen Erythrocytes take up oxygen and release carbon dioxide Reversible hydration of carbon dioxide Developmental Lineage of Pancreatic Ductal Cells TNFs bind their physiological receptors Transcriptional and post-translational regulation of MITF-M expression and activity ROS and RNS production in phagocytes Neutrophil degranulation Insulin receptor recycling Transferrin endocytosis and recycling Amino acids regulate mTORC1 Ion channel transport MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 26
1Fase 11
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 16 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Osteopetrose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

27 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2026 Feb 03

Autosomal dominant osteopetrosis (ADO) is a rare osteosclerotic disorder usually caused by missense variants in the CLCN7 gene, which results in impaired osteoclastic bone resorption. Penetrance is incomplete, and disease severity varies widely, even among relatives within the same family. Although ADO can cause visual loss, osteonecrosis, osteomyelitis, and bone marrow failure, the most common complication of ADO is fracture. We are conducting a natural history study to characterize disease progression and determinants of disease severity. We hypothesized that baseline BMD and bone turnover markers would correlate with self-reported fracture history. We report cross-sectional analysis of baseline data from the natural history study in 54 individuals (42 adults, 12 children). In adults, Z-scores for both volumetric (r = 0.87, p < .001) and areal BMD (aBMD) of the LS, and Z-scores for FN, and TH aBMD (r = 0.77 to 0.78; p < .001) were correlated with lifetime fracture number. Tartrate resistant acid phosphatase, a marker of osteoclast number, correlated positively with fracture (r = 0.52, p = .004) consistent with an adaptive response of higher numbers of osteoclasts among more severely affected individuals. However, fracture number correlated inversely with the bone resorption markers serum C-telopeptide (r = -0.60, p < .001) and urine N-telopeptide/creatinine ratio (r = -0.35, p = .047), suggesting that ADO subjects who have the most reduced osteoclast activity have a greater tendency to fracture. Correlation coefficients between fractures, BMD, and bone turnover markers were similar when limited to the 37 adults with disease-causing CLCN7 variants. There were no statistically significant differences between subjects with the most common CLCN7 variant (G215R), the most common variant in our cohort, compared to other CLCN7 variants with respect to fracture, bone density measures, or biochemical markers of bone turnover. These data demonstrate that bone density and biochemical bone turnover markers are indicators of ADO severity as defined by fracture number. Autosomal dominant osteopetrosis (ADO) is a rare genetic bone disorder characterized by abnormally dense but fragile bones. The severity of the condition can vary significantly, even among individuals within the same family. This natural history study aims to better understand the progression of ADO and identify factors that influence disease severity. Unlike osteoporosis, individuals with ADO who exhibit the highest bone density are paradoxically at the greatest risk for fractures. Furthermore, lower levels of biochemical markers of bone turnover were associated with both increased bone density and a higher incidence of fractures. Importantly, the severity of ADO did not correlate with the specific genetic variants responsible for the condition. In summary, ADO patients with the highest bone density have the most fractures. These findings suggest that both bone density and biochemical markers of bone turnover can serve as meaningful clinical endpoints in future trials evaluating potential therapies for ADO. TCIRG1-related osteopetrosis is characterized by growth deficiency, pathologic fractures of dense but brittle bones, limping gait with bone pain, hypocalcemia that can result in seizures, and secondary hyperparathyroidism. Advanced bone sclerosis results in extramedullary hematopoiesis, bone marrow failure, ocular complications with potential for blindness (optic nerve compression/atrophy and primary retinopathy), dental manifestations (delay in tooth eruption and dental caries), and deafness in some individuals. Craniofacial features can include macrocephaly, exophthalmos, hypertelorism, and micrognathia. There is wide variability in clinical severity. Severe osteopetrosis with infantile onset is the most common phenotype, potentially resulting in death at a young age in the absence of successful treatment. Individuals with mild TCIRG1-related osteopetrosis may have normal growth without hematologic or neurologic abnormalities. The diagnosis of TCIRG1-related osteopetrosis is established in a proband with characteristic clinical, laboratory, and imaging findings and biallelic pathogenic variants in TCIRG1 identified by molecular genetic testing. Note: Heterozygous TCIRG1 pathogenic variants have been rarely reported in individuals with TCIRG1-related osteopetrosis. Targeted therapies: Hematopoietic stem cell therapy (HSCT) for those with hematologic failure with imminent vision loss, severe osteopetrosis with bone marrow failure, or severe osteopetrosis in children younger than age one year, ideally prior to age ten months. Interferon gamma-1b (IFN-γ1b) may be considered in infantile TCIRG1-related osteopetrosis, to serve as a bridge to HSCT. Supportive care: Multidisciplinary management of complications includes treatment of fractures, skeletal deformities, and delayed healing per orthopedist; treatment of respiratory compromise per pulmonologist; calcium and vitamin D supplementation per endocrinologist; treatment of bone marrow failure and red blood cell transfusions per hematologist; dental treatment; management of hydrocephalus per neurosurgeon; treatment of hypocalcemia to prevent seizures; treatment of non-hypocalcemic seizures per neurologist; developmental and educational support; feeding therapy may become essential, requiring insertion of gastrostomy tube; optic nerve decompression and optic nerve sheath fenestration per neuro-ophthalmologist; surgical intervention for deafness per otolaryngologist; treatment of chronic/recurrent infections per infectious disease specialist; family and social work support. Surveillance: Assess for frequency of fractures, skeletal deformities, and bone pain at each visit; assess for respiratory compromise and frequency of infections in those with small-volume thorax; serum calcium and phosphate every six to 12 months and every three months in those on calcitriol therapy; 25-hydroxyvitamin D and intact parathyroid hormone every six to 12 months; serum creatinine, calculation of glomerular filtration rate, and urinary calcium-to-creatinine ratio every three months in those on calcitriol therapy; renal ultrasound annually in those on calcitriol therapy; complete blood count with differential every six to 12 months; dental evaluation more frequently than every six months; neurologic exam with EEG if seizures are suspected every six months; head imaging per neurologist; assess developmental progress, educational needs, feeding, and growth at each visit; ophthalmology evaluation every six months until age 18 years, then annually through adulthood, with visual field exams in those who are old enough to participate and MRI of the optic nerves as clinically indicated; annual audiology evaluation in childhood and as needed in adults; assess family and social work needs at each visit. Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic sibs of a proband with TCIRG1-related osteopetrosis caused by missense variants; sibs found to be heterozygous for a TCIRG1 missense variant should be monitored for manifestations of osteopetrosis. TCIRG1-related osteopetrosis is typically inherited in an autosomal recessive manner. Note: Heterozygous TCIRG1 pathogenic variants have been identified in affected individuals in one family with autosomal dominant osteopetrosis and one additional individual with a heterozygous de novo pathogenic variant. If both parents are known to be heterozygous for a TCIRG1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of having TCIRG1-related osteopetrosis, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial TCIRG1 pathogenic variants. To date, manifestations of TCIRG1-related osteopetrosis have not been reported in heterozygous family members of a proband with TCIRG1-related osteopetrosis; however, it is theoretically possible that heterozygous sibs may be at risk for TCIRG1-related osteopetrosis. Once the TCIRG1 pathogenic variants have been identified in an affected family member, heterozygote testing for at-risk family members and prenatal/preimplantation genetic testing are possible.

#2

Tcirg1 deficiency delays osteoarthritis progression by impairing lysosome acidification and peripheral accumulation in osteoclasts.

Frontiers in cell and developmental biology2025

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by articular cartilage loss and aberrant subchondral bone remodeling. "T-cell immune regulator 1" (Tcirg1), which encodes the a3 subunit of the V-ATPase, has been demonstrated to inhibit the formation of large osteoclasts by reducing intracellular calcium oscillations. Mutations in the Tcirg1 gene sequence have been associated with osteopetrosis by impairing lysosomal transport in osteoclasts. This study aims to assess the impact of Tcirg1 on OA progression and to explore its therapeutic potential for the disease treatment. Proteomic comparison of weight-bearing region (WBR) versus non-weight-bearing region (NWBR) of the subchondral bone was performed in 20 OA patients undergoing total knee arthroplasty. OA was then surgically induced in wild-type and Tcirg1-knockout mice by destabilization of the medial meniscus; disease severity and subchondral bone architecture were evaluated by histology and micro-CT. In vitro, primary bone marrow macrophages were differentiated into osteoclasts to assess the role of Tcirg1 in osteoclastogenesis, focusing on cell fusion, bone resorption, and lysosome acidification and distribution. Proteomic analysis revealed that TCIRG1 was significantly upregulated in the WBR compared to NWBR of subchondral bone in OA patients, with functional enrichment analysis indicating TCIRG1 correlation with lysosome-related biological processes. In the murine OA model, Tcirg1 expression increased in parallel with osteoclast activity, peaking at 4 weeks post-surgery, which coincided with severe subchondral bone loss. Tcirg1 deficiency in knockout mice delayed OA progression, as evidenced by reduced cartilage damage, improved subchondral bone mass, and decreased osteoclast activity. In vitro, Tcirg1 expression increased during osteoclast differentiation, and its knockdown inhibited osteoclast fusion and bone resorption by impairing lysosome acidification and peripheral accumulation. Tcirg1 regulates lysosome acidification and peripheral accumulation, thereby influencing osteoclast activity in the subchondral bone. Given that Tcirg1 knockdown was found to slow down the progression of OA, targeting Tcirg1 may serve as a potential therapeutic strategy for treating OA.

#3

In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking.

Nature2025 Jul

Lentiviral vector (LV)-mediated ex vivo gene therapy for haematopoietic stem and progenitor cells (HSPCs) has delivered on the promise of a 'one-and-done' treatment for several genetic diseases1. However, ex vivo manipulation and patient conditioning before transplantation are major hurdles that could be overcome by an in vivo approach. Here we demonstrate that in vivo gene delivery to HSPCs after systemic LV administration is enabled by the substantial trafficking of these cells from the liver to the bone marrow in newborn mice. We improved gene-transfer efficiency using a phagocytosis-shielded LV, successfully reaching bona fide HSPCs capable of long-term multilineage output and engraftment after serial transplantation, as confirmed by clonal tracking. HSPC mobilization further increased gene transfer, extending the window of intervention, although permissiveness to LV transduction declined with age. We successfully tested this in vivo strategy in mouse models of adenosine deaminase deficiency, autosomal recessive osteopetrosis and Fanconi anaemia. Interestingly, in vivo gene transfer provided a selective advantage to corrected HSPCs in Fanconi anaemia, leading to near-complete haematopoietic reconstitution and prevention of bone marrow failure. Given that circulating HSPCs in humans are also most abundant shortly after birth, in vivo HSPC gene transfer holds strong translational potential across multiple diseases.

#4

Identification of a novel mutation in the CLCN7 gene in pediatric osteopetrosis: case report.

Frontiers in pediatrics2025

Osteopetrosis, also known as osteosclerosis and marble-bone disease, is a rare genetic metabolic bone disorder caused by the dysplasia or dysfunction of osteoclasts, usually caused by variants of chloride voltage-gated channel 7 (CLCN7) gene. We retrospectively analyzed the clinical data of two children with osteopetrosis and their families. Whole-exome sequencing (WES) was used for genetic analysis, and Sanger sequencing confirmed possible pathogenic variants. In family 1, the proband harbored a novel mutation c.2351G>C (p.R784T) in CLCN7 gene. The initial symptom of proband 1 was a post-traumatic fracture, and imaging features was "sandwich cake" -like changes. In family 2, the proband harbored previously reported compound heterozygous variants in CLCN7 gene: c.899C>T (p.A300V) and c.1534G>A (p.G512R). Among them, c.1534G>A (p.G512R) was only recorded in clinvar and no reports of protein function prediction. The initial symptom of proband 2 was cough, and imaging features was "sandwich vertebrae". Our study expands the mutation spectrum of the CLCN7 gene and provides new insights into the pathogenesis of osteopetrosis.

#5

The correlation of intracranial parenchymal calcium score and the severity of neurological clinical presentation in carbonic anhydrase deficiency type 2.

Brain &amp; development2025 Feb

Carbonic anhydrase type II deficiency (CAII-D) syndrome is a rare autosomal recessive genetic disorder characterized by osteopetrosis, renal tubular acidosis, and brain calcifications. Understanding the clinical and radiological features of CAII-D is key to effective management. This study aimed to comprehensively analyze and measure intracranial parenchymal calcium score in pediatric CAII-D in relation to the severity of neurological clinical presentation. A retrospective chart review at King Saud University Medical City included pediatric CAII-D patients diagnosed between June 2015 and December 2022. Study variables included age, gender, genetic results, developmental status, developmental quotient (DQ), CT findings, optic canal diameter, intracranial calcium score, and neuropsychiatric symptoms. Ten CAII-D patients, median age 10.5 years, were included. Most patients displayed homozygous pathogenic CA2 gene variants. For neurodevelopmental symptoms, 60.0 % of patients presented with global developmental delay, 20.0 % had intellectual disability, and the remaining 20.0 % had normal development. The median DQ score was 63.50, with 80.0 % categorized as delayed. Neuropsychiatric disorders were present in 20.0 %. Optic nerve atrophy was observed in 22.2 %, while brain calcifications were present in 70.0 % of cases. Correlation analysis revealed no significant associations between intracranial parenchymal calcium score and age, DQ score, or optic canal diameter. Neurodevelopmental symptoms, neuropsychiatric symptoms, and DQ were not associated with intracranial parenchymal calcium score. Intraparenchymal calcifications in CAII-D are common but unrelated to developmental delay and neuropsychiatric symptoms, suggesting complex pathophysiology. Follow-up brain imaging may not aid in prognosis or severity assessment, highlighting the need for further research.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC63 artigos no totalmostrando 169

2025

Osteopetrosis misdiagnosed as congenital cytomegalovirus infection: A case report and literature review.

Medicine
2025

Tcirg1 deficiency delays osteoarthritis progression by impairing lysosome acidification and peripheral accumulation in osteoclasts.

Frontiers in cell and developmental biology
2026

Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025

Understanding rickets in osteopetrosis via a case: mechanisms and treatment implications.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Neuroaxonal Dystrophy With Osteopetrosis Associated With a Novel Biallelic Nonsense Homozygous Variant in BORCS5.

American journal of medical genetics. Part A
2025

Renal tubular acidosis: Varied aetiologies and clinical presentations: Three case reports.

World journal of nephrology
2025

Radiological diagnosis of infantile osteopetrosis in a 1-year-old with macrocephaly and jaundice.

Radiology case reports
2025

In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking.

Nature
2025

Bilateral Endoscopic Endonasal Optic Nerve Decompression in an Infant with Osteopetrosis: A Case Report.

Journal of neurological surgery reports
2025

Identification of a novel mutation in the CLCN7 gene in pediatric osteopetrosis: case report.

Frontiers in pediatrics
2025

A novel frameshift variant leads to familial osteopetrosis with variable phenotypes in a Chinese Han consanguineous family.

BMC medical genomics
2025

Evaluation of Quality and Bone Microarchitecture Alterations in Osteopetrosis Patients: Assessed by HR-PQCT.

The Journal of clinical endocrinology and metabolism
2025

Total shoulder arthroplasty in a patient with osteopetrosis: A case report.

Radiology case reports
2025

The correlation of intracranial parenchymal calcium score and the severity of neurological clinical presentation in carbonic anhydrase deficiency type 2.

Brain &amp; development
2024

Therapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis.

Biochemical pharmacology
2024

Malignant osteopetrosis of infancy: A case report.

International journal of surgery case reports
2024

Challenges of Hip and Knee Arthroplasty in Patients With Osteopetrosis.

The Journal of the American Academy of Orthopaedic Surgeons
2024

Molecular Heterogeneity of Osteopetrosis in India: Report of 17 Novel Variants.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2024

Impdh2 deficiency suppresses osteoclastogenesis through mitochondrial oxidative phosphorylation and alleviates ovariectomy-induced osteoporosis.

Biochemical and biophysical research communications
2024

Gain-of-function variants in CLCN7 cause hypopigmentation and lysosomal storage disease.

The Journal of biological chemistry
2024

Characterization of a spontaneous osteopetrosis model using RANKL-dysfunctional mice.

Tissue &amp; cell
2025

Patient-Reported Outcomes in Autosomal Dominant Osteopetrosis: Findings From the Osteopetrosis Registry Study.

The Journal of clinical endocrinology and metabolism
2024

Allogenic hematopoietic stem cell transplantation in an Iranian patient with osteopetrosis caused by carbonic anhydrase II deficiency: A case report.

Pediatric transplantation
2024

Identification of an novel genetic variant associated with osteoporosis: insights from the Taiwan Biobank Study.

JBMR plus
2024

Osteopetrosis and related osteoclast disorders in adults: A review and knowledge gaps On behalf of the European calcified tissue society and ERN BOND.

European journal of medical genetics
2024

Fosl2 Deficiency Predisposes Mice to Osteopetrosis, Leading to Bone Marrow Failure.

Journal of immunology (Baltimore, Md. : 1950)
2024

Osteopetrosis complicated by multilevel spondylolysis.

Radiology case reports
2024

Autosomal Dominant Osteopetrosis (ADO) Caused by a Missense Variant in the TCIRG1 Gene.

The Journal of clinical endocrinology and metabolism
2023

Successful complete oral rehabilitation of a patient with osteopetrosis with extensive pre-treatments, bone grafts, dental implants and fixed bridges: a multidisciplinary case report.

BMC oral health
2023

Cranial distraction osteogenesis for craniosynostosis associated with osteopetrosis: A case report.

Surgical neurology international
2023

Distinct ClC-6 and ClC-7 Cl- sensitivities provide insight into ClC-7's role in lysosomal Cl- homeostasis.

The Journal of physiology
2023

Fluconazole-Induced Protein Changes in Osteogenic and Immune Metabolic Pathways of Dental Pulp Mesenchymal Stem Cells of Osteopetrosis Patients.

International journal of molecular sciences
2023

The molecular spectrum of Turkish osteopetrosis and related osteoclast disorders with natural history, including a candidate gene, CCDC120.

Bone
2023

Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans.

Molecular therapy. Nucleic acids
2023

LRP5 high bone mass (Worth-type autosomal dominant endosteal hyperostosis): case report and historical review of the literature.

Archives of osteoporosis
2023

Osteosclerotic Metaphyseal Dysplasia Due to a Likely Pathogenic LRRK1 Variant as a Cause of Recurrent Long Bone Fractures.

JBMR plus
2023

CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs.

Frontiers in bioscience (Landmark edition)
2023

Molecular Mechanisms of Craniofacial and Dental Abnormalities in Osteopetrosis.

International journal of molecular sciences
2023

Brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS): new cases, systematic literature review, and associations with CSF1R-ALSP.

Orphanet journal of rare diseases
2023

GNAS gene mutations affecting XLαs and bone health: A long neglected relationship.

Clinical genetics
2023

LRP6 High Bone Mass Characterized in Two Generations Harboring a Unique Mutation of Low-Density Lipoprotein Receptor-Related Protein 6.

JBMR plus
2023

Clinical and Osteopetrosis-Like Radiological Findings in Patients with Leukocyte Adhesion Deficiency Type III.

Journal of clinical immunology
2023

Case report: Gene mutations and clinical characteristics of four patients with osteopetrosis.

Frontiers in pediatrics
2023

Autosomal dominant osteopetrosis.

Bone
2023

Clinical and genetic diagnosis of autosomal dominant osteopetrosis type II in a Chinese family: A case report.

World journal of clinical cases
2023

One half-century of advances in the evaluation and management of disorders of bone and mineral metabolism in children and adolescents.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2023

CLCN7, a gene shared by autosomal recessive and autosomal dominant osteopetrosis.

Bone
2023

Osteopetrosis: The patient point of view and medical challenges.

Bone
2022

Spectrum of Skeletal Imaging Features in Osteopetrosis: Inheritance Pattern and Radiological Associations.

Genes
2022

Imaging in osteopetrosis.

Bone
2022

Bone marrow transplantation as a therapy for autosomal dominant osteopetrosis type 2 in mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2022

Case report of mild TCIRG1-associated autosomal recessive osteopetrosis in Vietnam.

American journal of medical genetics. Part A
2022

Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases.

Frontiers in immunology
2022

Tyrosine Kinase Src Is a Regulatory Factor of Bone Homeostasis.

International journal of molecular sciences
2022

Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study.

Frontiers in endocrinology
2022

Open-Label Pilot Study of Interferon Gamma-1b in Patients With Non-Infantile Osteopetrosis.

JBMR plus
2022

The Treatment of Subtrochanteric Fracture with Reversed Contralateral Distal Femoral Locking Compression Plate (DF-LCP) Using a Progressive and Intermittent Drilling Procedure in Three Osteopetrosis Patients.

Orthopaedic surgery
2022

Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer.

Journal of cellular physiology
2021

Circular RNAs as potential regulators in bone remodeling: a narrative review.

Annals of translational medicine
2022

Broadening the phenotype of LRRK1 mutations - Features of malignant osteopetrosis and optic nerve atrophy with intrafamilial variable expressivity.

European journal of medical genetics
2021

Overlapping Phenotypes in Osteopetrosis and Pycnodysostosis in Asian-Indians.

Case reports in genetics
2022

SLC4A2 Deficiency Causes a New Type of Osteopetrosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2021

New Insights Into Osteoclast Biology.

JBMR plus
2023

A successful implant-supported fixed prosthesis in a patient with osteopetrosis: A clinical report.

The Journal of prosthetic dentistry
2022

A cross-sectional nationwide survey of osteosclerotic skeletal dysplasias in Japan.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
2021

Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre.

Orphanet journal of rare diseases
2021

A novel mutation in TNFRSF11A gene causes pediatric osteopetrosis: case report.

BMC surgery
2021

Managing challenging pain and irritability in OSTM1 mutation-related infantile malignant osteopetrosis.

BMJ case reports
2021

Autosomal recessive osteopetrosis: mechanisms and treatments.

Disease models &amp; mechanisms
2021

Efficient generation of osteoclasts from human induced pluripotent stem cells and functional investigations of lethal CLCN7-related osteopetrosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2021

Further expanding the mutational spectrum of brain abnormalities, neurodegeneration, and dysosteosclerosis: A rare disorder with neurologic regression and skeletal features.

American journal of medical genetics. Part A
2021

Insertion Mutation in Tnfrsf11a Causes a Paget's Disease-Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2021

Neurodegeneration Upon Dysfunction of Endosomal/Lysosomal CLC Chloride Transporters.

Frontiers in cell and developmental biology
2021

Further understanding on osteopetrotic femoral fractures: a case report and literature review.

BMC surgery
2021

The French multicentre elevated bone mass study: prevalence and causes.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2021

Hematopoietic stem cell transplantation in a patient with osteopetrosis and mutation in CLCN7: long-term follow-up.

Boletin medico del Hospital Infantil de Mexico
2021

CCDC154 Mutant Caused Abnormal Remodeling of the Otic Capsule and Hearing Loss in Mice.

Frontiers in cell and developmental biology
2021

West Syndrome Caused By a Chloride/Proton Exchange-Uncoupling CLCN6 Mutation Related to Autophagic-Lysosomal Dysfunction.

Molecular neurobiology
2021

Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal.

Molecular therapy. Methods &amp; clinical development
2021

Skeletal Biology and Disease Modeling in Zebrafish.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2020

Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.

International journal of molecular sciences
2021

The molecular structure and function of sorting nexin 10 in skeletal disorders, cancers, and other pathological conditions.

Journal of cellular physiology
2021

Large transient capacitive currents in wild-type lysosomal Cl-/H+ antiporter ClC-7 and residual transport activity in the proton glutamate mutant E312A.

The Journal of general physiology
2021

Pathobiologic Mechanisms of Neurodegeneration in Osteopetrosis Derived From Structural and Functional Analysis of 14 ClC-7 Mutants.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2021

Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH).

European journal of haematology
2021

A missense mutation sheds light on a novel structure-function relationship of RANKL.

Journal of cellular physiology
2020

Molecular insights into the human CLC-7/Ostm1 transporter.

Science advances
2020

High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6).

Bone
2020

Successful total hip arthroplasty for autosomal dominant osteopetrosis complicated by hip osteoarthritis: A case report and review of the literature.

Experimental and therapeutic medicine
2020

Adult Osteosclerotic Metaphyseal Dysplasia With Progressive Osteonecrosis of the Jaws and Abnormal Bone Resorption Pattern Due to a LRRK1 Splice Site Mutation.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2021

A Homozygous Mutation in 5' Untranslated Region of TNFRSF11A Leading to Molecular Diagnosis of Osteopetrosis Coinheritance With Wiskott-Aldrich Syndrome.

Journal of pediatric hematology/oncology
2021

Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.

Haematologica
2020

Kif1c regulates osteoclastic bone resorption as a downstream molecule of p130Cas.

Cell biochemistry and function
2020

Hematopoietic stem cell transplantation-induced bone remodeling in autosomal recessive osteopetrosis: Interaction between skeleton and hematopoietic and sensory nervous systems.

Bone
2020

A novel homozygous LRRK1 stop gain mutation in a patient suspected with osteosclerotic metaphyseal dysplasia.

Annals of human genetics
2019

Osteoclastogenesis inhibition by mutated IGSF23 results in human osteopetrosis.

Cell proliferation
2019

Lessons Learned from Long-Term Management of Hip Fracture in Patients with Osteopetrosis: A Report of Nine Hips in Five Patients.

Journal of bone metabolism
2019

Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.

Stem cell research &amp; therapy
2019

Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods.

Stem cell research &amp; therapy
2019

Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions.

Frontiers in immunology
2019

Chitosan/poly(γ-glutamic acid) nanoparticles incorporating IFN-γ for immune response modulation in the context of colorectal cancer.

Biomaterials science
2019

Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications.

Bone research
2019

Novel c.G630A TCIRG1 mutation causes aberrant splicing resulting in an unusually mild form of autosomal recessive osteopetrosis.

Journal of cellular biochemistry
2019

New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.

Bone
2019

TCIRG1 and SNX10 gene mutations in the patients with autosomal recessive osteopetrosis.

Gene
2019

Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years.

Blood advances
2019

Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2019

ClC-7 Regulates the Pattern and Early Development of Craniofacial Bone and Tooth.

Theranostics
2019

Generation of a human induced pluripotent stem cell line (BIHi002-A) from a patient with CLCN7-related infantile malignant autosomal recessive osteopetrosis.

Stem cell research
2019

Role of Semaphorins in Immunopathologies and Rheumatic Diseases.

International journal of molecular sciences
2019

Crocin attenuates methylglyoxal-induced osteoclast dysfunction by regulating glyoxalase, oxidative stress, and mitochondrial function.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
2018

Potential oligogenic disease of mental retardation, short stature, spastic paraparesis, and osteopetrosis.

The application of clinical genetics
2018

Sclerosing bone dysplasias.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2019

CLCN7 and TCIRG1 mutations in a single family: Evidence for digenic inheritance of osteopetrosis.

Molecular medicine reports
2018

Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.

JBMR plus
2018

Genetic Analysis of CLCN7 in an Old Female Patient with Type II Autosomal Dominant Osteopetrosis.

Endocrinology and metabolism (Seoul, Korea)
2019

LncRNA AK077216 promotes RANKL-induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45.

Journal of cellular physiology
2018

Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review.

Bone
2018

MiT family translocation renal cell carcinoma after malignant infantile osteopetrosis in childhood: a case report.

International journal of clinical and experimental pathology
2018

Whole exome sequencing identified two novel homozygous missense variants in the same codon of CLCN7 underlying autosomal recessive infantile malignant osteopetrosis in a Pakistani family.

Molecular biology reports
2018

CLC Chloride Channels and Transporters: Structure, Function, Physiology, and Disease.

Physiological reviews
2018

Case Report of Worth Syndrome and Chiari I Malformation: Unusual Association and Surgical Treatment.

World neurosurgery
2018

Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.

Pediatric blood &amp; cancer
2018

High bone mass in adults.

Joint bone spine
2018

Mouse models of SLC4-linked disorders of HCO3--transporter dysfunction.

American journal of physiology. Cell physiology
2017

Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.

Frontiers in medicine
2017

Bone quality changes associated with aging and disease: a review.

Annals of the New York Academy of Sciences
2017

Identification and in silico characterization of a novel p.P208PfsX1 mutation in V-ATPase a3 subunit associated with autosomal recessive osteopetrosis in a Pakistani family.

BMC medical genetics
2018

A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2018

Clinical Significance of DXA and HR-pQCT in Autosomal Dominant Osteopetrosis (ADO II).

Calcified tissue international
2017

IFN-γ alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils.

PloS one
2017

Decompressive Cranioplasty in a Patient with Osteopetrosis.

World neurosurgery
2017

Novel mutations of TCIRG1 cause a malignant and mild phenotype of autosomal recessive osteopetrosis (ARO) in four Chinese families.

Acta pharmacologica Sinica
2017

[Analysis of TCIRG1 gene mutation in a Chinese family affected with infantile malignant osteopetrosis].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2017

Guided growth for valgus deformity correction of knees in a girl with osteopetrosis: a case report.

Strategies in trauma and limb reconstruction
2018

Serum CTX levels and histomorphometric analysis in Src versus RANKL knockout mice.

Journal of bone and mineral metabolism
2017

Periodontal profile and radiographic characterization of the jaws in a patient with autosomal dominant osteopetrosis.

Endocrinology, diabetes &amp; metabolism case reports
2017

ClC Channels and Transporters: Structure, Physiological Functions, and Implications in Human Chloride Channelopathies.

Frontiers in pharmacology
2017

Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: implications in variant interpretation.

Genetics in medicine : official journal of the American College of Medical Genetics
2017

Role and mechanism of action of leucine-rich repeat kinase 1 in bone.

Bone research
2017

Case Report of Clinical Vignette: Osteopetrosis.

Military medicine
2017

Hematopoietic stem cell transplantation corrects osteopetrosis in a child carrying a novel homozygous mutation in the FERMT3 gene.

Bone
2017

The Formation of Calcified Nanospherites during Micropetrosis Represents a Unique Mineralization Mechanism in Aged Human Bone.

Small (Weinheim an der Bergstrasse, Germany)
2017

Raine Syndrome (OMIM #259775), Caused By FAM20C Mutation, Is Congenital Sclerosing Osteomalacia With Cerebral Calcification (OMIM 259660).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2017

Homozygous deletion of RAG1, RAG2 and 5' region TRAF6 causes severe immune suppression and atypical osteopetrosis.

Clinical genetics
2016

PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis.

JCI insight
2017

Lysosomal Ca2+ Signaling is Essential for Osteoclastogenesis and Bone Remodeling.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2016

Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation.

American journal of medical genetics. Part A
2016

Genetics of osteoporosis: searching for candidate genes for bone fragility.

Archives of endocrinology and metabolism
2016

Novel CLCN7 mutation identified in a Han Chinese family with autosomal dominant osteopetrosis-2.

Molecular pain
2016

Characterization of a Relatively Malignant Form of Osteopetrosis Caused by a Novel Mutation in the PLEKHM1 Gene.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2017

The use of whole exome sequencing for the diagnosis of autosomal recessive malignant infantile osteopetrosis.

Clinical genetics
2016

Oral Rehabilitation of an Osteopetrosis Patient with Osteomyelitis.

Case reports in dentistry
2016

Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2016

Osteopetrosis in two siblings: two case reports.

BMC research notes
2016

Loss of PPARγ in endothelial cells leads to impaired angiogenesis.

Journal of cell science
2016

Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning.

Pediatric blood &amp; cancer
2016

A novel mutation and a known mutation in the CLCN7 gene associated with relatively stable infantile malignant osteopetrosis in a Chinese patient.

Gene
2016

Potential blindness in children of patients with hereditary bone disease.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2016

Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation.

Annals of the rheumatic diseases
2016

Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II).

Journal of bone and mineral metabolism
2015

A tale of two CLCs: biophysical insights toward understanding ClC-5 and ClC-7 function in endosomes and lysosomes.

The Journal of physiology
2015

Hematopoietic stem cell transplantation for infantile osteopetrosis.

Blood
2015

The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2015

Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.

Expert opinion on therapeutic targets
2015

Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.

Pediatric transplantation
2015

An Adolescent Case of Osteopetrosis with Portal Hypertension as well as Mandibula Osteomyelitis.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2015

Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.

Metabolic brain disease
2015

SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Osteopetrose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Osteopetrose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Fractures are highly correlated with bone density and inversely correlated with bone turnover markers in autosomal dominant osteopetrosis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research· 2026· PMID 40913471mais citado
  2. Tcirg1 deficiency delays osteoarthritis progression by impairing lysosome acidification and peripheral accumulation in osteoclasts.
    Frontiers in cell and developmental biology· 2025· PMID 40995561mais citado
  3. In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking.
    Nature· 2025· PMID 40437086mais citado
  4. Identification of a novel mutation in the CLCN7 gene in pediatric osteopetrosis: case report.
    Frontiers in pediatrics· 2025· PMID 40276109mais citado
  5. The correlation of intracranial parenchymal calcium score and the severity of neurological clinical presentation in carbonic anhydrase deficiency type 2.
    Brain &amp; development· 2025· PMID 39667299mais citado
  6. [Function of the CLC chloride channels and their implication in human pathology].
    Nephrologie· 2002· PMID 12087807recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2781(Orphanet)
  2. MONDO:0017198(MONDO)
  3. GARD:4155(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1755568(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Osteopetrose
Compêndio · Raras BR

Osteopetrose

ORPHA:2781 · MONDO:0017198
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive, X-linked recessive
CID-10
Q78.2 · Osteopetrose
CID-11
Ensaios
2 ativos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0029454
EuropePMC
Wikidata
Wikipedia
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades